



GPCR MOLECULAR PHARMACOLOGY AND DRUG TARGETING

Shifting Paradigms and New Directions

Edited by
ANNETTE GILCHRIST



 **WILEY**

Table of Contents

Cover

Table of Contents

Half title page

Title page

Copyright page

Dedication

PREFACE

CONTRIBUTORS

**CHAPTER 1 The Evolution of
Receptors: From On-Off Switches to
Microprocessors**

1.1. INTRODUCTION

1.2. THE RECEPTOR AS AN ON-OFF SWITCH

**1.3. HISTORICAL BACKGROUND AND
CLASSICAL RECEPTOR THEORY**

**1.4. THE OPERATIONAL MODEL OF DRUG
ACTION**

1.5. RECEPTOR ANTAGONISM

1.6. SPECIFIC MODELS OF GPCRs (7TM RECEPTORS)

1.7. THE RECEPTOR AS MICROPROCESSOR: TERNARY COMPLEX MODELS

1.8. RECEPTORS AS BASIC DRUG RECOGNITION UNITS

1.9. RECEPTOR STRUCTURE

1.10. FUTURE CONSIDERATIONS

CHAPTER 2 The Evolving Pharmacology of GPCRs

2.1. AGONISTS, NEUTRAL ANTAGONISTS, AND INVERSE AGONISTS

2.2. LDTRS/PROTEAN AGONISM

2.3. MOLECULAR MECHANISMS OF GPCR LIGAND BINDING

2.4. TWO GPCR LIGANDS BINDING AT ONCE – CONCEPT OF ALLOSTERISM

2.5. GPCR DIMERIZATION

2.6. FUTURE PERSPECTIVES
ACKNOWLEDGMENTS

CHAPTER 3 The Emergence of Allosteric Modulators for G Protein-Coupled Receptors

3.1. INTRODUCTION

3.2. FOUNDATIONS OF ALLOSTERIC RECEPTOR THEORY

3.3. MODELS FOR UNDERSTANDING THE EFFECTS OF ALLOSTERIC MODULATORS

3.4. TYPES OF ALLOSTERIC MODULATORS AND THEIR PROPERTIES

3.5. DETECTION AND QUANTIFICATION OF ALLOSTERIC INTERACTIONS

3.6. SOME EXAMPLES OF GPCR ALLOSTERIC MODULATORS

3.7. CONCLUDING REMARKS

CHAPTER 4 Receptor-Mediated G Protein Activation: How, How Many, and Where?

4.1. THE MECHANICAL PROBLEM—THREE DIFFERENT SOLUTIONS

4.2. RECEPTOR MONOMERS-DIMERS-OLIGOMERS: ONE SIZE FITS ALL?

4.3. CORRALS, FENCES, RAFTS—ARE THERE PRIVILEGED PLACES FOR GPCR ACTIVATION?

ACKNOWLEDGMENTS

CHAPTER 5 Molecular Pharmacology of Frizzleds—with Implications for Possible Therapy

5.1. INTRODUCTION

5.2. FRIZZLEDS AS WNT RECEPTORS

5.3. FRIZZLED SIGNALING

5.4. FRIZZLEDS—PHYSIOLOGY AND POSSIBLE THERAPY

ACKNOWLEDGMENTS

CHAPTER 6 Secretin Receptor Dimerization: A Possible Functionally Important Paradigm for Family B G Protein-Coupled Receptors

6.1. METHODOLOGICAL APPROACHES TO GPCR OLIGOMERIZATION

6.2. STRUCTURAL THEMES FOR GPCR OLIGOMERIZATION

6.3. FUNCTIONAL EFFECTS OF GPCR OLIGOMERIZATION

6.4. SECRETIN RECEPTOR OLIGOMERIZATION

CHAPTER 7 Past and Future Strategies for GPCR Deorphanization

7.1. INTRODUCTION

7.2. CURRENT STRATEGIES TO IDENTIFY THE LIGAND AND FUNCTION OF ORPHAN 7TM PROTEINS

7.3. FUNCTIONAL ASSAYS FOR DEORPHANIZATION

7.4. FUTURE DIRECTIONS AND NEW CONCEPTS

7.5. CONTROVERSIAL ISSUES

ACKNOWLEDGMENTS

CHAPTER 8 High-Throughput GPCR Screening Technologies and the Emerging Importance of the Cell Phenotype

8.1. INTRODUCTION

8.2. HOW ARE GPCR DRUGS DISCOVERED?

8.3. GPCR DEPENDENCE ON G PROTEINS

8.4. TECHNOLOGIES FOR GPCR COMPOUND SCREENING AND DRUG DISCOVERY

8.5. IMPORTANCE OF TARGET CELLS IN GPCR HTS ASSAYS

8.6. SUMMARY

CHAPTER 9 Are “Traditional” Biochemical Techniques Out of Fashion in the New Era of GPCR Pharmacology?

9.1. OVERVIEW

9.2. RECEPTOR BINDING ASSAYS

9.3. METHODS FOR MEASUREMENT OF cAMP

9.4. CONCLUSIONS

CHAPTER 10 Fluorescence and Resonance Energy Transfer Shine New Light on GPCR Function

10.1. OVERVIEW

10.2. INTRODUCTION

10.3. LABELING GPCRs WITH FLUORESCENT TAGS

10.4. DETECTION OF FLUORESCENCE AND BIOLUMINESCENCE

10.5. FLUORESCENCE-BASED ASSAYS TO STUDY RECEPTOR LOCALIZATION, TRAFFICKING AND RECEPTOR FUNCTION

10.6. RESONANCE ENERGY TRANSFER, A TOOL TO GET NEW INSIGHTS INTO GPCR FUNCTION

10.7. ANALYSIS OF STEADY-STATE PROTEIN-PROTEIN INTERACTION BY MEANS OF RET

10.8. KINETIC ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS BY MEANS OF FRET

10.9. DETECTION OF RECEPTOR FUNCTION BY FLUORESCENCE RESONANCE ENERGY

CHAPTER 11 Integration of Label-Free Detection Methods in GPCR Drug Discovery

11.1. OVERVIEW

11.2. INTRODUCTION

11.3. LABEL-FREE TECHNOLOGIES—PAST AND PRESENT

11.4. DISCUSSION

ACKNOWLEDGMENTS

CHAPTER 12 Screening for Allosteric Modulators of G Protein-Coupled

Receptors

12.1. INTRODUCTION

12.2. THE ALLOSTERIC TERNARY COMPLEX MODEL, RADIOLIGAND BINDING, AND AFFINITY

12.3. BEYOND AFFINITY—FUNCTIONAL ASSAYS, EFFICACY, AND ALLOSTERIC AGONISM

12.4. ALLOSTERIC MODULATOR TITRATION CURVES

12.5. THE IMPACT OF FUNCTIONAL ASSAY FORMAT ON ALLOSTERIC MODULATOR SCREENING

12.6. TAKING ADVANTAGE OF STRUCTURAL UNDERSTANDING OF ALLOSTERIC BINDING SITES

12.7. SUMMARY AND FUTURE DIRECTIONS

CHAPTER 13 Ultra-High-Throughput Screening Assays for GPCRs

13.1. INTRODUCTION

13.2. ASSAY TYPES FOR GPCRs IN uHTS

13.3. SUMMARY ACKNOWLEDGMENTS

CHAPTER 14 New Techniques to Express and Crystallize G Protein-Coupled Receptors

14.1. INTRODUCTION

**14.2. KEY PROBLEMS LIMITING
PRODUCTION OF 3D GPCR STRUCTURES**
14.3. HISTORY OF GPCR STRUCTURES
**14.4. THE SEARCH FOR OTHER GPCR
STRUCTURES**
**14.5. PROTEIN PURIFICATION AND
SOLUBILIZATION**
14.6. IN CUBO CRYSTALLIZATION
14.7. ENGINEERING RECEPTOR STABILITY
14.8. STRUCTURES OF THE β_2 AR
14.9. THE ADENOSINE A_{2a} RECEPTOR
**14.10. CONCLUSIONS AND FUTURE
DEVELOPMENTS**
ACKNOWLEDGMENTS

CHAPTER 15 Structure and Modeling of GPCRs: Implications for Drug Discovery

15.1. INTRODUCTION
15.2. HIGH-RESOLUTION GPCR MODELING
**15.3. CONSTRUCTING AND EVALUATING
HOMOLOGY MODELS OF OTHER RECEPTOR
TYPES**
**15.4. MODELING GPCR FUNCTIONAL
FEATURES—ANALYSIS OF ACTIVATION AND
SIGNALING**
**15.5. BEYOND CLASS A: MODELING OF
OTHER GPCR FAMILIES**
15.6. SUMMARY AND CONCLUSIONS

ACKNOWLEDGMENTS

CHAPTER 16 X-Ray Structure Developments for GPCR Drug Targets

16.1. OVERVIEW

16.2. INTRODUCTION

16.3. CLASS A GPCRs

16.4. CLASS C GPCRs

16.5. CONCLUSIONS

CHAPTER 17 Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein- Coupled Receptors

17.1. OVERVIEW

17.2. INTRODUCTION

17.3. NDI AND THE V2R

17.4. RP AND THE RHODOPSIN RECEPTOR

17.5. IHH AND THE GONADOTROPIN- RELEASING HORMONE RECEPTOR

17.6. OTHER HUMAN DISEASES CAUSED BY INACTIVATING MUTATIONS IN GPCRs

17.7. CONSIDERATIONS FOR THE THERAPEUTIC USE OF PHARMACOLOGICAL CHAPERONES

17.8. CONCLUDING REMARKS

ACKNOWLEDGMENTS

Index

Color Plates

GPCR MOLECULAR PHARMACOLOGY AND DRUG TARGETING

GPCR MOLECULAR PHARMACOLOGY AND DRUG TARGETING

SHIFTING PARADIGMS AND
NEW DIRECTIONS

Edited by

Annette Gilchrist

Department of Pharmaceutical Sciences
Midwestern University, Downers Grove, Illinois

 **WILEY**

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2010 John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.

Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care

Department within the United States at (800) 762-2974,
outside the United States at (317) 572-3993 or fax (317)
572-4002.

Wiley also publishes its books in a variety of electronic
formats. Some content that appears in print may not be
available in electronic formats. For more information about
Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

GPCR molecular pharmacology and drug targeting : shifting
paradigms and new directions / edited by Annette Gilchrist.

p. ; cm.

Includes index.

ISBN 978-0-470-30778-6 (cloth)

ISBN 978-1-118-03517-7 (ebk)

1. G proteins. 2. Drug targeting. I. Gilchrist, Annette.

[DNLM: 1. Receptors, G-Protein-Coupled-physiology. 2. Drug
Delivery Systems. 3. Molecular Structure. QV 38 G725 2010]

QP552.G16G627 2010

612'.015756-dc22

2009052133

*To Josen and Finn, who arrived somewhere in the middle of
all of this ...*

PREFACE

Although G protein-coupled receptors (GPCRs) have been the subject of study since the early days of pharmacology, our understanding of this large family of receptors continues to evolve. As a result, texts that discuss these receptors must constantly be rewritten and revised as emerging concepts are brought forth. Although many texts focus on GPCRs, none provide an overall look at the molecular pharmacology of this important target class. This book presents an up-to-date review on how scientists are thinking about GPCRs.

Early work includes the lock and key model of Fisher, and “receptive substances” to explain the biological actions of exogenous chemicals on cell “receptors,” and Clark’s occupancy theory that introduced the idea that the effect of an agonist is proportional to the number of occupied receptors. In the 1960s, the concept of intrinsic activity was introduced to explain the observation that not every agonist of a given receptor induced the same maximum effect. Compounds reaching the maximum were referred to as full agonist and other agonists were named partial agonist. This model was later extended to include drug efficacy and the system-independent concept of intrinsic efficacy. The mathematics applied in the models were relatively simple and allowed calculations to be made on affinity and activity. Looking back, it seems remarkable that most of these concepts were developed when little information on the biochemical nature of receptors or the underlying molecular mechanisms involved in signal transduction were available.

I have been working in the field of GPCRs for about 15 years, a time dwarfed by many of the contributing authors, who are well recognized as being experts in the field. In this time period, many of the basic pharmacology concepts for GPCRs have undergone radical changes. Yet, if one looks back, it seems that years before their general acceptance,

there was research to support the paradigm shifts. For example, in 1989 Costa and Herz described antagonists with negative intrinsic activity at wild-type δ -opioid receptors (*PNAS* 1989 86: 7321-7325). Many subsequent studies have confirmed that GPCR proteins can signal in an agonist-independent, constitutive manner, and the concept of inverse agonism is now accepted and included in pharmacology textbooks. But in its early days, the concept of inverse agonism was hotly debated. Thus, the way we think about GPCRs, their basal activity, how they get activated, how they communicate the signal across the cell membrane, how they couple to each other as well as to other receptors and other membrane proteins, how their mutations lead to disease, and the many ways in which they can be screened for compounds that modulate them are constantly changing.

This textbook will serve as a resource for any scientists (e.g., pharmacologists, chemists, biologists) investigating GPCRs in both academia and industry (pharmaceutical/biotechnology). The book provides a general overview of GPCRs in terms of their biology and pharmacology, as well as recent developments including structure, deorphanization, dimerization, functional selectivity, and accessory proteins. In addition, it presents detailed methods on how to express, manipulate, and measure GPCRs. It is important to recognize that emerging concepts have shaped not only our understanding of GPCR pharmacology but also the drug discovery process itself. Recognition that most of the compounds initially considered to be competitive antagonists were inverse agonists, and studies indicating that the therapeutic outcome of inverse agonists and neutral antagonists can be different, led many companies to initiate drug discovery efforts specifically aimed at identifying inverse agonists. As a result, it is envisaged that this book on the shifting paradigms to GPCR

pharmacology will be an essential resource for scientists working to identify compounds that selectively target members of this diverse family.

The book is organized into 17 chapters; the first seven chapters deal with the evolving pharmacology that surrounds this family, including chapters discussing allosteric modulators, receptor dimerization, GPCR deorphanization, G protein activation, and the Frizzled family. The next six chapters deal with methods to screen GPCRs, and include chapters on cell phenotype, “traditional” biochemical techniques, resonance energy transfer, label-free detection, and approaches for ultra-high-throughput screening. The next three chapters present GPCR structures, new ways to express and crystallize the receptors, as well as computational studies such as modeling and rational drug design. The final chapter describes the use of pharmacological chaperones for diseases caused by GPCR mutations.

ANNETTE GILCHRIST

Chicago College of Pharmacy

Midwestern University

CONTRIBUTORS

Ruben Abagyan, Bioinformatics and Systems Biology
Graduate Program, University of California, La Jolla, CA

Elfrida R. Benjamin, Amicus Therapeutics, Cranbury, NJ

Magdalena Birker-Robaczewska, Actelion
Pharmaceuticals Ltd., Allschwil, Switzerland

Michel Bouvier, Département de Biochimie, Université
de Montréal, Montréal, Quebec, Canada

Moritz Bünemann, Department of Pharmacology and
Toxicology, Philipps-Universität Marburg, Marburg,
Germany

Nathalie Clement, Institut Cochin, Université Paris
Descartes, Department of Cell Biology, Paris, France

Arthur Christopoulos, Monash Institute of
Pharmaceutical Sciences and Department of
Pharmacology, Monash University, Victoria, Australia

Maria Teresa Dell'Anno, Department of Psychiatry,
Neurobiology, Pharmacology and Biotechnologies,
University of Pisa, Pisa, Italy

Maoqing Dong, Department of Molecular Pharmacology
and Experimental Therapeutics, Mayo Clinic, Scottsdale,
AZ

Richard M. Eglen, PerkinElmer Life and Analytical
Sciences, Waltham, MA

James C. Errey, Heptares Therapeutics Limited, BioPark, Welwyn Garden City, Hertfordshire, UK

Michael Freissmuth, Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria

John Gatfield, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

Karen J. Gregory, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

Christian W. Gruber, Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria

Ingrid Gsandtner, Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria

Kaleeckal G. Harikumar, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, AZ

Stephen J. Hill, The University of Nottingham, Institute of Cell Signalling, School of Biomedical Sciences, Queen's Medical Centre, Nottingham, UK

Carsten Hoffmann, Department of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany

Nicholas D. Holliday, The University of Nottingham, Institute of Cell Signalling, School of Biomedical Sciences, Queen's Medical Centre, Nottingham, UK

Ralf Jockers, Institut Cochin, Université Paris Descartes,
Department of Cell Biology, Paris, France

Vsevolod Katritch, Skaggs School of Pharmacy and
Pharmaceutical Sciences, La Jolla, CA

Terry Kenakin, Biochemical Reagents and Assay
Development, GlaxoSmithKline Research and
Development, Research Triangle Park, NC

Priya Kunapuli, In Vitro Sciences, External Discovery
and Preclinical Sciences, Merck & Co., West Point, PA

Christopher Langmead, Heptares Therapeutics
Limited, BioPark, Welwyn Garden City, UK

Angélique Levoye, Unité de Pathogénie Virale,
Department of Virology, Institut Pasteur, Paris, France

Fiona H. Marshall, Heptares Therapeutics Limited,
BioPark, Broadwater Road, Welwyn Garden City,
Hertfordshire, UK

Lauren T. May, The University of Nottingham, Institute
of Cell Signalling, School of Biomedical Sciences, Queen's
Medical Centre, Nottingham, UK

Maria Rosa Mazzoni, Department of Psychiatry,
Neurobiology, Pharmacology and Biotechnologies,
University of Pisa, Pisa, Italy

Laurence J. Miller, Department of Molecular
Pharmacology and Experimental Therapeutics Mayo
Clinic, Scottsdale, AZ

Oliver Nayler, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

Terry Reisine, Independent Consultant, Los Angeles, CA

Patricia René, Département de Biochimie, Université de Montréal, Montréal, Quebec, Canada

Kimberly A. Reynolds, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX

Michael Sabio, Lundbeck Research USA, Paramus, NJ

Gunnar Schulte, Section of Receptor Biology and Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

Patrick M. Sexton, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

John Simms, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

Elodie Tenconi, Institut Cochin, Université Paris Descartes, Department of Cell Biology, Paris, France

Sidney W. Topiol, Lundbeck Research USA, Paramus, NJ

Celine Valant, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Victoria, Australia

Kenneth J. Valenzano, Amicus Therapeutics, Cranbury,
NJ

CHAPTER 1

The Evolution of Receptors: From On-Off Switches to Microprocessors

TERRY KENAKIN

**Biochemical Reagents and Assay Development,
GlaxoSmithKline Research and Development,
Research Triangle Park, NC**

... Try to imagine a pharmacology course that made no mention of receptors ...'

—Humphrey Rang, 2006

1.1. INTRODUCTION

The evolution of the receptor concept is traced from the turn of the century where the receptor was an organizational concept to the present day where seven transmembrane (7TM) receptors are considered to be complex control units for cellular function. Drug receptor effect can be quantified without knowledge of molecular mechanism through the operational model of drug action. Alternatively, biochemical knowledge of the receptor as an independent protein unit recognizing both external chemicals and cytosolic protein independently can be used to understand ligand-specific receptor effects and how these might be exploited therapeutically.

1.2. THE RECEPTOR AS AN ON-OFF SWITCH

Historically, the concept of drug receptors began as an abstract idea and continued throughout pharmacology for another 70–80 years as such. Models considering receptors essentially had drugs activate (as a switch) a black box to produce tissue response. It is useful first to consider receptors as pharmacological switches since the theories used to describe drug action in these systems lay the foundation for the more mechanistically driven models of receptors in use today. These ideas have formed the basis for quantitative receptor theory on which new information about the biochemistry and structure of receptors has been added. These will then be discussed in terms of specific mechanistic models of 7TM receptor function and how these assist in the quantification of drug effect.

1.3. HISTORICAL BACKGROUND AND CLASSICAL RECEPTOR THEORY

What is considered a “given” today, namely that drugs interact with specific binding sites on the cell membrane called receptors, is an extremely important tenet of pharmacology. As stated by Rang [1], it indeed was “Pharmacology’s big idea.” The main reason it is such an important cornerstone of pharmacology is that it introduces order into the apparent chaos of physiology. For example, a simple molecule such as epinephrine mediates a myriad of physiological processes. A large subset of these, namely cardiac chronotropy, inotropy, lusitropy, vascular relaxation, lacrimal, pancreatic, and salivary gland secretion,

bronchiole, uterine and urinary bladder muscle relaxation, decreased stomach motility, skeletal muscle tremor, and melatonin synthesis are mediated by a small subset of membrane-bound proteins, specifically β_1 - and β_2 -adrenoceptors. This immediately puts order in the collection of physiological processes in that it gives them a common place to start, namely the interaction of epinephrine with the receptor. This order fits in well with the discipline of medicinal chemistry in that chemists have access to the processes for potential control.

At the turn of the twentieth century, different groups carried out research that caused them to postulate the existence of control points on cells that responded to chemicals, that is, receptors. For example, Paul Ehrlich (1854-1915) carried out studies on agent "606" (salvarsan) for syphilis. His work with dyes and bacteria led him to propose that there are "chemoreceptors" (actually a collection of "amboreceptors," "triceptors," and "polyceptors") on parasites, cancer cells, and microorganisms that could be exploited therapeutically [2]. In Cambridge, John Newport Langley (1852-1926) studied the drug jaborandi (contains the alkaloid pilocarpine) and atropine and concluded that receptors were "switches" that received and generated signals and that these switches could be activated or blocked by specific molecules [2]. However, it is A.J. Clark (1885-1941) who is considered the father of modern receptor pharmacology. Clark was the first to suggest, from studies of acetylcholine and atropine, that a unimolecular interaction occurs between a drug and a "substance on the cell." As he put it [3] ...

... it is impossible to explain the remarkable effects observed except by assuming that drugs unite with receptors of a highly specific pattern....

In fact, it was Clark who described pharmacological phenomena in chemical terms [3, 4], a concept readily

accepted today, but quite heretical in Clark's time. The prevailing concepts guiding physiology at the turn of the century were rooted in homeopathic theories (i.e., a fundamental theory centered on the surface tension of the cell membrane) like the Arndt-Schulz Law and Weber-Fechner Law [2]. A generally accepted statement to describe physiologic phenomena was simply that "certain phenomena occur frequently."

One of Clark's most valuable contributions to pharmacology was the application of mathematical rules to the behavior of biological systems. Thus, the dose-response curve became the common currency of pharmacology, and its judicious use in the work of Clark and others built the framework for what had become known as "receptor theory," namely the application of simple thermodynamic rules to pharmacological systems.

An early example of mathematics applied to the study of receptors was provided by A.V. Hill, a student of Langley. He expressed the time course of contraction of frog rectus abdominus to the agonist nicotine (N) through an equilibrium concentration-response curve of the form:

$$(1.1) \quad Y = \frac{N}{k' + kN} - M$$

where Y is contraction height, M is threshold, and k', k are constants. While this work predated the routine use of binding isotherms to receptor work considerably, Hill lost interest in the approach, and it was left to Irving Langmuir, a chemist at General Electric Company in the United States, to devise an equation for the quantification of molecules binding to a surface, in particular, chemicals to metal filaments for light bulbs. Thus, the Langmuir adsorption isotherm quantifies the fraction of the substance bound to a

surface (the pharmacological counterpart being receptor, denoted ρ_A) by a molecule $[A]$ as:

(1.2)
$$\rho_A = \frac{[A]}{[A] + K_A}$$

where K_A is the ratio of what Langmuir referred to as the “rate of evaporation” of the substance away from the surface (pharmacologically, the rate of offset of the molecule from the receptor) divided by the “rate of condensation” of the molecule toward the surface (pharmacologically, the rate of onset toward the receptor). In pharmacological terms, the specific terminology for molecules that produced such activation is “agonist.” While mechanistically, this equation is based on thermodynamic principles governing agonist binding to receptors, operationally, it also defines the universally observed relationship between agonists and the pharmacological responses they induce to tissues and cells. Thus, any observed receptor-mediated response in any tissue can be summarized by a form of the Langmuir isotherm where the fractional maximum given by Equation 1.2 is multiplied by the maximal response observed from the preparation ($\text{Response}_A = \rho_A \cdot E_{\max}$):

(1.3)
$$\text{Response}_A = \frac{[A] \cdot E_{\max}}{[A] + EC_{50}}$$

where EC_{50} refers to the concentration of agonist A that produces half the maximal response to drug A . It should be noted that Equation 1.3 is written for a system demonstrating a Hill coefficient (in honor of A.V. Hill) of unity. If there is cooperativity in the system (either in the binding of the drug to the receptor [*vide infra*] or in the